AstraZeneca’s Experimental Drug Camizestrant Shows Promise in Advanced Breast Cancer Trial

AstraZeneca’s experimental treatment, camizestrant, has shown significant promise in improving survival for patients with advanced hormone receptor-positive, HER2-negative breast cancer, according to interim results from a late-stage clinical trial.

The SERENA-6 trial tested camizestrant in combination with a standard-of-care therapy that suppresses tumor growth proteins. The study found that the drug improved progression-free survival, meaning it helped patients live longer without their disease worsening when used as a first-line treatment.

“These findings mark an important step forward in our mission to provide more effective treatment options for patients battling advanced breast cancer,” AstraZeneca stated.

Earlier trials had already highlighted camizestrant’s effectiveness, particularly in patients with ESR1 mutations, a genetic alteration known to make breast cancer resistant to traditional hormone therapies. The drug works by degrading estrogen receptors, preventing the hormone from fueling cancer growth.

The promising results suggest that camizestrant could become a new standard of care for breast cancer patients, particularly those whose tumors have stopped responding to existing treatments. AstraZeneca plans to continue further studies to confirm the long-term benefits of the drug.